SkyePharma looks for cost savings from Muttenz research lab shake-up

SkyePharma has entered into a consultation process that could lead to a reduction of approximately 20 per cent of its 101-strong workforce in Muttenz, Switzerland. The proposed steps are intended to improve the company's competitiveness and generate SFr 2.6 million (£1.8 million) of annual operating costs.

At the same time, SkyePharma has agreed to sub-let part of its laboratory space in Muttenz and sell some of its surplus laboratory equipment to Aenova. The latter plans to use the space to expand its own non-competing oral product development activities. The changes will not affect relationships with existing or potential customers and SkyePharma will continue to provide its existing range of oral and inhalation drug-delivery products.

Looking forward, SkyePharma intends to make greater use of third-party sub-contracting for certain aspects of the oral product development process and Aenova has agreed to be a sub-contractor for this purpose. There will be no transfer or disposal of any business, technology or intellectual property to Aenova.

This article is tagged to:
Sector: Medical Devices
Geography: Switzerland

Enter your details to read the full article

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.